Cargando…

Lithium Monotherapy in Graves Thyrotoxicosis

Lithium is not commonly used to treat thyrotoxicosis, and there are few reports in the literature of its use as initial therapy in thyrotoxicosis. We describe the case of a patient with Graves thyrotoxicosis and ophthalmopathy, on a background of autoimmune neutropenia, treated successfully with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkworthy, James, Kirresh, Omar, Chakera, Ali, Ahmed, Fahad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580469/
https://www.ncbi.nlm.nih.gov/pubmed/37908984
http://dx.doi.org/10.1210/jcemcr/luad094
_version_ 1785121947032485888
author Larkworthy, James
Kirresh, Omar
Chakera, Ali
Ahmed, Fahad
author_facet Larkworthy, James
Kirresh, Omar
Chakera, Ali
Ahmed, Fahad
author_sort Larkworthy, James
collection PubMed
description Lithium is not commonly used to treat thyrotoxicosis, and there are few reports in the literature of its use as initial therapy in thyrotoxicosis. We describe the case of a patient with Graves thyrotoxicosis and ophthalmopathy, on a background of autoimmune neutropenia, treated successfully with relatively long-term lithium monotherapy. Lithium was used at a lower dose and longer duration than previously reported on, to good effect. We demonstrate that lithium is an important and useful option for those who are unable to tolerate thionamide therapy.
format Online
Article
Text
id pubmed-10580469
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105804692023-10-31 Lithium Monotherapy in Graves Thyrotoxicosis Larkworthy, James Kirresh, Omar Chakera, Ali Ahmed, Fahad JCEM Case Rep Case Report Lithium is not commonly used to treat thyrotoxicosis, and there are few reports in the literature of its use as initial therapy in thyrotoxicosis. We describe the case of a patient with Graves thyrotoxicosis and ophthalmopathy, on a background of autoimmune neutropenia, treated successfully with relatively long-term lithium monotherapy. Lithium was used at a lower dose and longer duration than previously reported on, to good effect. We demonstrate that lithium is an important and useful option for those who are unable to tolerate thionamide therapy. Oxford University Press 2023-07-27 /pmc/articles/PMC10580469/ /pubmed/37908984 http://dx.doi.org/10.1210/jcemcr/luad094 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Larkworthy, James
Kirresh, Omar
Chakera, Ali
Ahmed, Fahad
Lithium Monotherapy in Graves Thyrotoxicosis
title Lithium Monotherapy in Graves Thyrotoxicosis
title_full Lithium Monotherapy in Graves Thyrotoxicosis
title_fullStr Lithium Monotherapy in Graves Thyrotoxicosis
title_full_unstemmed Lithium Monotherapy in Graves Thyrotoxicosis
title_short Lithium Monotherapy in Graves Thyrotoxicosis
title_sort lithium monotherapy in graves thyrotoxicosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580469/
https://www.ncbi.nlm.nih.gov/pubmed/37908984
http://dx.doi.org/10.1210/jcemcr/luad094
work_keys_str_mv AT larkworthyjames lithiummonotherapyingravesthyrotoxicosis
AT kirreshomar lithiummonotherapyingravesthyrotoxicosis
AT chakeraali lithiummonotherapyingravesthyrotoxicosis
AT ahmedfahad lithiummonotherapyingravesthyrotoxicosis